ICIrazú Contreras-Yáñez

Irazú Contreras-Yáñez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irazú Contreras-Yáñez has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence and transient impact of childhood abuse and neglect on health-related quality of life in Mexican patients with early rheumatoid arthritis

    by Guillermo Guaracha-Basáñez, Irazú Contreras-Yáñez, Abril Verónica Mendoza-Vigueras, Frida Carvajal-Medina, Ana Belén Ortiz-Haro, Loraine Ledón-Llanes, Virginia Pascual-Ramos

  • Another look at the intertendinous connections: a dynamic study based on palpation, ultrasonography, and dissection

    by Jorge Murillo-González, Esperanza Naredo, Virginia Pascual-Ramos, José Ramón Mérida-Velasco, Otto Olivas-Vergara, Irazú Contreras-Yáñez, Irene Piñeiro-Bugallo, Arantxa Torres-Rosello, Juan J. Canoso


  • The superficial transverse metacarpal ligament and the interdigital web. A proof-of-concept study based on palpation, ultrasonography, casts, and dissection

    by Jorge Murillo-González, Esperanza Naredo, Virginia Pascual-Ramos, José Ramón Mérida-Velasco, Otto Olivas-Vergara, Irazú Contreras-Yáñez, Irene Piñeiro-Bugallo, Arantxa Torres-Rosello, Juan J. Canoso

    Purpose This study, based on palpation, ultrasonography, casts, and dissection, aimed to identify the superficial transverse metacarpal ligament and further characterize the interdigital web, including skin gliding, slope’s angle and length, histology, and dynamic changes during finger abduction. Methods The preferred hand of 10 healthy participants was studied by palpation and ultrasonography. Alginate casts of the webspace were obtained from seven healthy volunteers. Five cadaver hands were dissected for illustration and to histologically evaluate the dorsal and palmar web. Descriptive and non-parametric statistics were used. Results The superficial transverse metacarpal ligament was detected through palpation in finger abduction at the webs, with an estimated width of about 7.1 mm. Ultrasonography was used to trace this ligament throughout its course and measure its thickness, with a median value of approximately 0.46 mm. Both palpation and ultrasonography revealed its proximal transverse and distal arciform fibres. The latter extended along the proximal phalanges. At the fleshy web, skin gliding was assessed by palpation. Both ultrasonography and dissection allowed for measuring the skin, which was thicker on the palmar side. Elastic fibres predominated on the dorsal side, and dense collagen on the palmar side. The alginate casts revealed that during finger abduction, the dorsal web opened as a curved triangle with the web’s edge, digital extensions, and dorsal skin as a checkrein. Conclusions Palpation, ultrasonography, and dissection detected complementary features of the natatory ligament and the interdigital space. The alginate casts revealed that the dorsal web opened as a curved triangle. Dissection provided detailed information about the involved structures.


  • Open Access

    The impact of underlying RMD diagnosis on dignity landscape in patients with systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis

    by Virginia Md Pascual-Ramos, Irazú Sw Contreras-Yáñez, Maximiliano Cuevas-Montoya, Guillermo Md Guaracha-Basáñez, Mario García-Alanís, Oscar Md Rodríguez-Mayoral, Harvey Max Chochinov

    Distress related to perceived dignity (DPD) has been associated with mental health comorbidity, intensive treatment, and quality of life among patients with rheumatic diseases (RMDs). Within the RMD landscape, each individual diagnosis might present with distinctive sociodemographic characteristics, clinical phenotypes, and prognoses, all of which shape the patient’s perceived dignity. The study utilized a cross-sectional design to determine the impact of underlying RMD diagnosis on DPD phenomenon and to compare DPD patterns in patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc). Between February 2022 and April 2023, consecutive outpatients diagnosed with SLE, RA, and SSc completed the Mexican version of the Patient Dignity Inventory (PDI-Mx), along with additional patient-reported outcomes, which assessed participants perceived mental health, resilience, disease activity/severity, family functioning, fatigue, disability, quality of life, and satisfaction with medical care (SMC). A score of 54.5 or higher on the PDI-Mx was defined as indicating DPD. The attending rheumatologist determined the adequacy of control for the underlying RMD, comorbidities, and RMD diagnosis. Multivariate logistic regression analyses were performed to identify the factors associated with DPD. There were 137 patients (38.3%) with SLE, 124 (34.6%) with RA, and 97 (27.1%) with SSc. Among them, 88 patients (24.6%) had DPD. SSc diagnosis (exp ß, 95% confidence interval [95% CI] and P value: 0.291, 0.109–0.773, .013), World Health Organization Quality of Life—Brief questionnaire score (0.953, 0.926–0.980, .001 [irrespective of the specific dimension]), age (0.970, 0.942–0.999, .040), at least moderate severity for depression (9.512, 4.019–22.021, ≤.0001), 1-year previous hospitalization (2.673, 1.249–5.723, .011), Health Assessment Questionnaire Disability Index score (2.495, 1.409–4.420, .002), Routine Assessment of Patient Index Data score (1.084, 1.015–1.158, .016), and Functional Assessment of Chronic Illness Therapy score (1.023, 1.006–1.041, .009) were the factors associated with DPD, with an R² of 0.627. Overall, scores for PDI-Mx and its corresponding domains were similar across the 3 patient groups. Among patients with SLE, RA, and SSc, a diagnosis of SSc was found to be a protective factor against DPD. We also identified other protective factors, including age and quality of life. On the other hand, mental health comorbidity, disability, and more severe clinical phenotypes were associated with an increased risk of DPD.


  • Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study

    by George A. Karpouzas, Sarah R. Ormseth, Piet Van Riel, Elena Myasoedova, Miguel A. Gonzalez-Gay, Alfonso Corrales, Solbritt Rantapaa-Dahlqvist, Petros Sfikakis, Patrick Dessein, Carol A. Hitchon, et al.

    Objective Patients with rheumatoid arthritis (RA) experience higher cardiovascular risk. Methotrexate may decrease this risk, although it is unclear whether males and females similarly benefit. We explored the influence of sex on the effect of methotrexate use on cardiovascular risk in RA. Methods An observational cohort of 4362 patients, 3223 (73.9%) females, without cardiovascular disease were included from an international cardiovascular consortium for RA. Outcomes were (a) major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, or stroke and (b) any ischemic cardiovascular events (iCVE) including MACE, angina, revascularization, transient ischemic attack, and peripheral arterial disease. The effects of sex, prevalent methotrexate use at enrollment visit and their interaction on MACE and iCVE were assessed with multivariable Cox regression models, reporting adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results There were 237 first MACE and 358 first iCVE. The sex by methotrexate interaction was significant for MACE (p = 0.005) and iCVE (p = 0.006), suggesting the effect of methotrexate use on cardiovascular risk differed among males and females. In males, methotrexate use associated with lower risk of MACE (HR 0.32, [95% CI 0.12–0.83]) and iCVE (HR 0.43 [95% CI 0.21–0.85]). In females, methotrexate use was not associated with MACE (p = 0.267) or iCVE (p = 0.407). In sensitivity analyses, models with inverse probability of treatment weighting and models additionally adjusting for inflammation yielded similar results. Conclusion Methotrexate use associated with cardiovascular benefit in males but not females with RA and the effect was independent of inflammation.


  • Open Access

    Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

    by George Athanasios Karpouzas, Sarah R Ormseth, Piet Leonardus Cornelis Maria van Riel, Miguel A Gonzalez-Gay, Alfonso Corrales, Solbritt Rantapää-Dahlqvist, Petros P Sfikakis, Patrick Dessein, Linda Tsang, Carol Hitchon, et al.

    Objectives Chronic inflammation promotes cardiovascular risk in rheumatoid arthritis (RA). Biological disease-modifying antirheumatic drugs (bDMARDs) improve disease activity and cardiovascular disease outcomes. We explored whether bDMARDs influence the impact of disease activity and inflammatory markers on long-term cardiovascular risk in RA. Methods We studied 4370 participants without cardiovascular disease in a 10-country observational cohort of patients with RA. Endpoints were (1) major adverse cardiovascular events (MACE) encompassing myocardial infarction, stroke and cardiovascular death; and (2) any ischaemic cardiovascular events (iCVE) including MACE plus revascularisation, angina, transient ischaemic attack and peripheral arterial disease. Results Over 26 534 patient-years, 239 MACE and 362 iCVE occurred. The interaction between 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) and bDMARD use was significant for MACE (p=0.017), suggesting the effect of DAS28-CRP on MACE risk differed among bDMARD users (n=515) and non-users (n=3855). DAS28-CRP (per unit increase) is associated with MACE risk in bDMARD non-users (HR 1.21 (95% CI 1.07 to 1.37)) but not users (HR 0.69 (95% CI 0.40 to 1.20)). The interaction between CRP (per log unit increase) and bDMARD use was also significant for MACE (p=0.011). CRP associated with MACE risk in bDMARD non-users (HR 1.16 (95% CI 1.04 to 1.30)), but not users (HR 0.65 (95% CI 0.36 to 1.17)). No interaction was observed between bDMARD use and DAS28-CRP (p=0.167) or CRP (p=0.237) for iCVE risk. Conclusions RA activity and inflammatory markers associated with risk of MACE in bDMARD non-users but not users suggesting the possibility of biological-specific benefits locally on arterial wall independently of effects on systemic inflammation.


  • Patients Journey Before Early Rheumatoid Arthritis Diagnosis Contributes to disease's Activity Level

    by Guillermo A. Guaracha-Basáñez, Irazú Contreras-Yáñez, Ana B. Ortiz Haro, Virginia Pascual-Ramos

    Introduction: The help-seeking process in rheumatoid arthritis (RA) patients is challenging, and its study is limited in Latin America. The study describes the real-life journey before patients' incorporation into an early arthritis clinic (EAC) and its impact on baseline and 1-year cumulative disease activity levels. Patients and Methods: The patient's journey was assessed through a questionnaire that captured the patient's path from the first disease-related symptom to the initial assessment in the EAC. A disease activity (28 joints evaluated)–erythrocyte sedimentation rate (DAS28-ESR) score >5.1 defined a high-disease activity level. The mean of individual consecutive DAS28-ESR scores summarized cumulative DAS28-ESR. Multiple logistic regression analysis identified factors associated with a DAS28-ESR score >5.1 at the first assessment. Linear regression analysis assessed the impact of general practitioner (GP)–first consultant and time on disease-modifying antirheumatic drugs (DMARDs) on baseline and cumulative DAS28-ESR scores. Results: Through January 2023, the EAC had 241 RA patients, among whom 209 (86.7%) completed the patients' journey questionnaire (PJQ) and 176 (84.2%) at least 1 year of follow-up. A GP was the first consultant in 76.6% of the patients, and only 12.4% were prescribed DMARDs. Patients had additional evaluations with either rheumatologists (38.6%) or other specialists (31.6%), and half of them were initiated DMARDs. GP-first consultant (adjusted odds ratio: 2.314, 95% confidence interval: 1.190–4.500, p = 0.013) and time on DMARDs (adjusted odds ratio: 0.738, 95% confidence interval: 0.585–0.929, p = 0.010) were associated with baseline DAS28-ESR score >5.1. The B coefficient magnitudes for GP-first consultant and time on DMARDs to predict cumulative DAS28 progressively decreased during the first year of follow-up. Conclusions: Patients' journey before recent-onset RA diagnosis predicts first-year disease activity levels.


  • Sociocultural and moral narratives influencing the decision to vaccinate among rheumatic disease patients: a qualitative study

    by Amaranta Manrique de Lara, Tirsa Colmenares-Roa, Virgina Pascual-Ramos, José Francisco Moctezuma-Rios, Irazú Contreras-Yañez, Guillermo Arturo Guaracha-Basañez, Everardo Álvarez-Hernández, Graciela Meza-López Y Olguín, Ingris Peláez-Ballestas

    Introduction/objectives Vaccination is a process that involves individual, social, and ethical aspects, beyond public governance of vaccines or vaccination as a public health concern. The aim of this study is to describe the sociocultural and moral narratives that influence the decision to vaccinate in general and to vaccinate against COVID-19 specifically, among patients at the rheumatology units of two hospitals. Methods Qualitative study involving individual semi-structured interviews following an interview guide. We conducted a thematic analysis using the ATLAS.ti software, with further triangulation to verify concordance and aid in the interpretation of the data from a medical anthropology framework and using a narrative ethics approach to gain insight into the participants’ underlying moral values. Results We interviewed 37 patients in total, along with 3 rheumatologists. Five core themes emerged from the analysis to understand the decision to vaccinate: (1) information about vaccines and disease, (2) perceived risk–benefit of vaccination, (3) the physician–patient relationship, (4) governance of vaccination programs, (5) attitudes towards vaccines. Individual and family experiences with vaccination are diverse depending on the type of vaccine. The COVID-19 vaccine, as a new medical technology, is met with more controversy leading to hesitancy. Conclusions The decision to vaccinate among Mexican rheumatic disease patients can sometimes involve doubt and distrust, especially for those with a lupus diagnosis, but ultimately there is acceptance in most cases. Though patients make and value autonomous decisions, there is a collective process involving sociocultural and ethical aspects. Key points • The complexity of vaccine decision-making is better identified through a narrative, qualitative approach like the one used in this study, as opposed to solely quantitative approaches • Sociocultural and moral perspectives of vaccination shape decision-making and, therefore, highlight the importance of including patients in the development of effective clinical practice guidelines as well as ethically justified public policy • Sociohistorical context and personal experiences of immunization influence vaccine decision-making much more than access to biomedical information about vaccines, showing that approaches based on the information deficit model are inadequate to fight vaccine hesitancy


  • Open Access

    The COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study

    by Alfonso Gastelum-Strozzi, Diana Elsa Flores-Alvarado, Virginia Pascual-Ramos, Everardo Álvarez-Hernández, César Francisco Pacheco-Tena, Guillermo Arturo Guaracha-Basáñez, Conrado García García, Susana Aideé González-Chávez, José Francisco Moctezuma-Ríos, Amaranta Manrique de Lara, et al.

    The attitudes toward emerging COVID-19 vaccines have been of great interest worldwide, especially among vulnerable populations such as patients with rheumatic and musculoskeletal diseases (RMDs). The aim of this study was to analyze the relationship between the nationwide number of COVID-19 cases and deaths, and vaccine acceptance or hesitancy of patients with RMDs from four patient care centers in Mexico. Furthermore, we explored differences in acceptance according to specific diagnoses: rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This ecological study was a secondary analysis of a cross-sectional study using a validated questionnaire to measure vaccine acceptance. We generated a global Likert scale to evaluate overall attitudes toward the COVID-19 vaccine. We analyzed data from 1336 patients from March to September 2021: 85.13% (1169) were women, with a mean age of 47.87 (SD 14.14) years. The most frequent diagnoses were RA (42.85%, 559) and SLE (27.08%, 393). 635(47.52%) patients were unvaccinated, 253(18.93%) had one dose and 478(35.77%) had two doses. Of all participating patients, 94% were accepting toward the COVID-19 vaccine. Vaccine acceptance remained consistently high throughout the study. However, differences in vaccine acceptance are identified when comparing diagnoses. The peak of the national epidemic curve coincided with an increase in hesitancy among patients with RA. Contrastingly, patients with SLE became more accepting as the epidemic curve peaked. Mexican patients show high acceptance of the COVID-19 vaccine, influenced in part by a patient’s specific diagnosis. Furthermore, vaccine acceptance increased mirroring the curve of COVID-19 cases and deaths in the country. This should be taken into consideration when updating recommendations for clinical practice.


  • Perception of risk and impact of the COVID-19 pandemic on patients with rheumatic diseases: a case–control study

    by Alfonso Gastelum-Strozzi, Virginia Pascual, Adolfo Hernández-Garduño, José Francisco Moctezuma-Rios, Guillermo Arturo Guaracha-Basañez, Thalya Sotelo, Conrado Garcia-Garcia, Irazú Contreras-Yañez, Everardo Álvarez-Hernández, Claudia Infante-Castañeda, et al.

    Objectives Risk perception of the COVID-19 pandemic may affect chronic disease outcomes among patients with rheumatic diseases (RD). To describe and compare the perception of risk and effects of the COVID-19 pandemic on patients with RD from two health care centers compared with a control group. Methods A retrospective case–control study was conducted. Patient respondents completed an online survey to measure risk perception and effects of the COVID-19 pandemic. The case group consisted of patients with a confirmed diagnosis of RD, coming from two third-level health care centers. The control group was a population group without RD from a public university. Results A total of 3944 participants were included: 986 patients with an RD (cases) from the two hospital centers and 2958 controls without RD. A greater perception of risk severity and perception of contagion was observed in the group of patients with RD, OR: 1.70, 95% CI 1.44‒2.01 and OR: 2.0, 95% CI 1.79‒2.23, respectively; more significant deterioration in family life OR: 1.14, 95% CI 1.01‒1.29; greater economic impact, OR 3.94, 95% CI 3.48‒4.46; as well as negative emotions and feelings (alarmed, anxiety, depression, confusion, fear, isolation, and discrimination). This impact was maintained when the model was adjusted for comorbidities. Conclusion In the face of an unexpected and catastrophic event such as the COVID-19 pandemic, patients with RD report apparently greater impact on their mental state and economic situation than the control population, as well as increased perception of discrimination. Key Points • The multidisciplinary analyses of risk perception are required to promote actions that can enhance the preparedness and responses of public efforts for possible future pandemics in a way that considers the specific needs of vulnerable people like patients with rheumatic diseases. • Identifying risk perceptions of possible effects of the pandemic, sources of communication, and opinions is essential to ensure self-care in rheumatic disease. • The impact of COVID-19 has been much greater for people with rheumatic disease, especially in terms of the perceived severity of the pandemic, impacts on family and economy, preventive behaviors, and uncertainty.